Medigen Biotechnology Corporation Statistics
Medigen Biotechnology Corporation (3176) Stock Statistics & Valuation Metrics
Total Valuation
Medigen Biotechnology Corporation has a market cap or net worth of $4.42B. The enterprise value is $6.91B.
- Market Cap
- $4.42B
- Enterprise Value
- $6.91B
Share Statistics
Medigen Biotechnology Corporation has 139,306,750 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 139,306,750
- Owned by Insiders
- ―
- Owned by Institutions
- 2.51%
Financial Efficiency
Medigen Biotechnology Corporation’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -2.76%.
- Return on Equity (ROE)
- -0.07
- Return on Assets (ROA)
- -0.02
- Return on Invested Capital (ROIC)
- -2.76%
- Return on Capital Employed (ROCE)
- -0.03
- Revenue Per Employee
- 23.62M
- Profits Per Employee
- -1.62M
- Employee Count
- 67
- Asset Turnover
- 0.26
- Inventory Turnover
- 1.25
Valuation Ratios
The current PE Ratio of Medigen Biotechnology Corporation is -18.02. Medigen Biotechnology Corporation’s PEG ratio is 0.14.
- PE Ratio
- -18.02
- PS Ratio
- 3.46
- PB Ratio
- 3.06
- Price to FCF
- -9.84
- Price to Operating Cash Flow
- -101.33
- PEG Ratio
- 0.14
Income Statement
In the last 12 months, Medigen Biotechnology Corporation had revenue of 1.58B and earned -108.80M in profits. Earnings per share was -0.78.
- Revenue
- 1.58B
- Gross Profit
- 857.73M
- Operating Income
- -156.99M
- Pretax Income
- -218.60M
- Net Income
- -108.80M
- EBITDA
- 18.64M
- Earnings Per Share (EPS)
- -0.78
Cash Flow
In the last 12 months, operating cash flow was -44.62M and capital expenditures -419.93M, giving a free cash flow of -464.55M billion.
- Operating Cash Flow
- -44.62M
- Free Cash Flow
- -464.55M
- Free Cash Flow per Share
- -3.37
Dividends & Yields
Medigen Biotechnology Corporation pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -10.28%
- Earnings Yield
- -5.64%
Stock Price Statistics
- Beta
- 0.40
- 52-Week Price Change
- 10.61%
- 50-Day Moving Average
- 35.86
- 200-Day Moving Average
- 33.75
- Relative Strength Index (RSI)
- 30.64
- Average Volume (3m)
- 626.65K
Important Dates
Medigen Biotechnology Corporation upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Medigen Biotechnology Corporation as a current ratio of 4.68, with Debt / Equity ratio of 61.49%
- Current Ratio
- 4.68
- Quick Ratio
- 3.90
- Debt to Market Cap
- 0.15
- Net Debt to EBITDA
- -19.89
- Interest Coverage Ratio
- -6.79
Taxes
In the past 12 months, Medigen Biotechnology Corporation has paid 77.35M in taxes.
- Income Tax
- 77.35M
- Effective Tax Rate
- -0.35
Enterprise Valuation
Medigen Biotechnology Corporation EV to EBITDA ratio is -124.41, with an EV/FCF ratio of -11.39.
- EV to Sales
- 4.01
- EV to EBITDA
- -124.41
- EV to Free Cash Flow
- -11.39
- EV to Operating Cash Flow
- -118.63
Balance Sheet
Medigen Biotechnology Corporation has $2.72B in cash and marketable securities with $1.72B in debt, giving a net cash position of $1.01B billion.
- Cash & Marketable Securities
- $2.72B
- Total Debt
- $1.72B
- Net Cash
- $1.01B
- Net Cash Per Share
- $7.23
- Tangible Book Value Per Share
- $33.51
Margins
Gross margin is 47.33%, with operating margin of -18.42%, and net profit margin of -19.12%.
- Gross Margin
- 47.33%
- Operating Margin
- -18.42%
- Pretax Margin
- -21.75%
- Net Profit Margin
- -19.12%
- EBITDA Margin
- -3.22%
- EBIT Margin
- -17.58%
Analyst Forecast
The average price target for Medigen Biotechnology Corporation is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -19.26%
- EPS Growth Forecast
- -230.04%
